-

Afrin® WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays – Because One Sick Kid Can Throw Everything Off in An Instant

Children’s Afrin® products provide ridiculously FAST nasal congestion relief, so busy parents can get their families back on track. The WOW is REAL!

WHIPPANY, N.J.--(BUSINESS WIRE)--Afrin®, the #1 doctor and pharmacist recommended nasal spray brand1, announced today the launch of Children’s Afrin®, the children's acute medicated nasal spray that works fast and lasts up to 12 hours. Available in retail stores nationwide, the line of children’s medicated consumer products includes Afrin® Extra Moisturizing Stuffy Nose Spray and Afrin® No Drip Extra Moisturizing Stuffy Nose Spray.

Children’s Afrin® provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies. The children’s medicated product line offers nasal spray products for children two to six and six and up:

  • Afrin® Extra Moisturizing Stuffy Nose Pump Mist, for ages two to six years old, is specially formulated for young children and unblocks a stuffy nose fast
  • Afrin® No Drip Extra Moisturizing Stuffy Nose Pump Mist, for ages six years old and up, targets nasal congestion in seconds without dripping down the nose or throat

“There’s nothing worse than when you’re almost out the door, and your child runs over with their stuffy and snotty nose complaining of being sick because you know your plans for the day have been thwarted. That’s why we’re excited to bring the power of Afrin’s fast congestion relief to the whole family, so all ages can breathe more freely,” said Catherine Vennat, VP/GM, Upper Respiratory, Bayer Consumer Health U.S. “Children suffering from colds or allergies now have access to nasal congestion relief that works fast and allows children to feel like themselves again, and their busy parents to get their families back on track while juggling multiple responsibilities.”

The nasal sprays offer fast relief to children for up to 12 hours, providing comfort to children and their parents, all day or all night. Children’s Afrin® Medicated Nasal Sprays are available at mass retail locations. For more information, please visit https://www.afrin.com/ or follow us on Instagram and Twitter.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

1 Pharmacy Times Survey 2020

Contacts

Danielle Goonan
Senior Director, Strategic Communications, Brand PR, Influencer & Social, Bayer Consumer Health U.S.
danielle.goonan@bayer.com

Bayer


Release Versions

Contacts

Danielle Goonan
Senior Director, Strategic Communications, Brand PR, Influencer & Social, Bayer Consumer Health U.S.
danielle.goonan@bayer.com

More News From Bayer

Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that a broad set of data from its stroke franchise will be presented at the 2026 European Stroke Organisation Conference (ESOC), including new late-breaking analyses from its global, landmark Phase III OCEANIC-STROKE study of asundexian, an investigational oral Factor XIa inhibitor. In total, 13 abstracts will be presented, including four OCEANIC-STROKE sub-analyses. Additionally, Bayer will present nine real-world analyses examining stroke...

Post Durnell Argument Scenario Statements – Attributable to Monsanto

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--“We appreciate the Court’s careful consideration of FIFRA’s Uniformity language and how its federal preemption provision applies to state-based label warnings. “We believe the U.S. Government and the Company made persuasive arguments that state-based warning claims ‘in addition to or different from’ warning labels approved by EPA under FIFRA, as in Durnell, are preempted, and this is necessary to avoid a patchwork of 50 different warning labels....

Media Alert for Durnell Supreme Court Argument

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--On April 27th, Monsanto will argue before the U.S. Supreme Court in Durnell v. Monsanto, a Roundup case involving the application of federal preemption under FIFRA. A favorable ruling by the Supreme Court would provide essential regulatory clarity for companies who seek to bring currently approved and new products to market, addressing their ability to serve U.S. farmers and consumers. Former Solicitor General Paul Clement will argue the case fo...
Back to Newsroom